Back

레메디 KOSDAQ

387690

Suggest a tag

Watch

Notes Naver Finance

Meeting voting results

Extraordinary 2026.10.27

Participation 37.2% Minority 0.0% DART

1 사내이사 조봉호 선임의 건 Approved Approval 100.0%

Previous meeting results

Financial indicators

Market cap

788 × 100M KRW

PBR

4.20

PER

13.3

ROE

58.11%

Dividend yield

Debt-to-equity ratio

158.0%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 Semiannual report (2026-06-30)

Controlling shareholders total

43.91%

Minority shareholders (excl. related parties)

40.59%

Large outside holders (1%+)

15.50% (11 people)

Treasury shares

0.00%

Total shareholders

343 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

Consolidated Annual financial data is not available yet.

레메디 — Quarterly Consolidated Financial statements
Item	26/6
Income statement
Revenue	61.8 × 100M KRW
Operating profit	28.3 × 100M KRW
Net income	18.6 × 100M KRW
Operating margin	45.81%
Balance sheet
Total assets	324.3 × 100M KRW
Total liabilities	164.6 × 100M KRW
Total equity	159.8 × 100M KRW
Cash flow statement
Consolidated Quarterly cash flow data is not available yet.
Investment indicators
Debt-to-equity ratio	103.02%
EPS	-
Detailed accounts
Current assets	170.9 × 100M KRW
Non-current assets	153.4 × 100M KRW
Current liabilities	118.5 × 100M KRW
Non-current liabilities	46.1 × 100M KRW
Equity attributable to owners	157.3 × 100M KRW
Share capital	31.9 × 100M KRW
Capital surplus	127.3 × 100M KRW
Other equity	3.8 × 100M KRW
Accumulated other comprehensive income	127 × 10,000 KRW
Retained earnings	-5.7 × 100M KRW
Non-controlling interests	2.5 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

레메디 — Annual Legacy summary & estimates Financial statements
Item	2023	2024	2025	2026 E
Income statement
Revenue	69 × 100M KRW	134 × 100M KRW	146 × 100M KRW	240 × 100M KRW
Operating profit	-23 × 100M KRW	9 × 100M KRW	28 × 100M KRW	68 × 100M KRW
Net income	-37 × 100M KRW	7 × 100M KRW	51 × 100M KRW	-
Operating margin	-33.52%	7.02%	18.80%	28.33%
Balance sheet
Total assets	-	-	-	-
Total liabilities	-	-	-	-
Total equity	-	-	-	-
Investment indicators
ROE	-54.23%	16.42%	58.11%	-
Debt-to-equity ratio	239.27%	187.35%	157.99%	-
Separate total assets	-	-	-	-
EPS	KRW -573	KRW 142	KRW 777	KRW 972
PER	-	-	-	10.63×
PBR	0.00	0.00	0.00	-
Dividend per share	-	-	-	-

레메디 — Quarterly Legacy summary & estimates Financial statements
Item	26/6 Consolidated
Income statement
Revenue	61.8 × 100M KRW
Operating profit	28.3 × 100M KRW
Net income	18.6 × 100M KRW
Operating margin	45.81%
Balance sheet
Total assets	324.3 × 100M KRW
Total liabilities	164.6 × 100M KRW
Total equity	159.8 × 100M KRW
Investment indicators
Debt-to-equity ratio	103.02%
EPS	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Property data is not available yet.

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Articles of incorporation analysis

Articles of incorporation analysis is not available yet.

Executive compensation

Executive compensation data is not available yet.

Controlling shareholders

Controlling shareholder data is not available yet.

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
이레나	44.26%	3,375,334	+44.26%	신규 상장	일반	2026-07-20
김현섭	2.21%	168,224	+2.21%	발행회사의 코스닥시장 신규상장(2026,07,13)으로 인한 주식등의 대량보유자 편입및 같은날 잘내매도로 인한 보유비율 5% 미만 하락	약식	2026-07-14

Auditors

Analysis date 2026.08.26 11:50

Auditor	Type	Term start	Term end	Tenure	D-day
전영택	Auditor	-	2029.03.31	6 years	D-876

Executives

Name	Position	Category	Age	Term end
서현숙	고문	미등기	Age 77	-
박영일	CSO	Inside director	Age 68	D-511
노철호	부사장	Inside director	Age 67	D-876
조봉호	대표이사	Inside director	Age 66	Expired
김영석	기타 비상무 이사	Inside director	Age 64	D-876
송수현	사외이사	Outside director	Age 61	D-332
박준석	CFO	미등기	Age 59	-
김희철	이사	미등기	Age 58	-
이레나	고문	미등기	Age 58	-
김웅회	이사	미등기	Age 54	-
서주형	사외이사	Outside director	Age 53	D-332
최태운	상무	미등기	Age 52	-
전영택	감사	감사	Age 50	D-876
김권용	이사	미등기	Age 49	-
조성호	상무	미등기	Age 49	-

DART disclosures

Loading disclosures…

레메디 KOSDAQ

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Corporate shareholders Collapse Corporate shareholders

Articles of incorporation analysis Collapse Articles of incorporation analysis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures